OMEICOS Therapeutics GmbH - News

OMEICOS Secures Continued BMBF Support with New €1.7M Research Grant to Advance its Novel Approach to Treat Cardiovascular Diseases

Clinical Trial in Atrial Fibrillation Ongoing as OMEICOS Evaluates Therapeutic Paradigm in Additional Indication Areas

Berlin, Germany, June 07, 2017 — OMEICOS Therapeutics, a biopharmaceutical company developing first-in-class small molecule therapeutics for the prevention and treatment of cardiovascular diseases including atrial fibrillation, today announced the approval of a new grant by the German Ministry of Education and Research (BMBF). The grant of approximately €1.7 million covers half of the investment needed to advance an OMEICOS research project with the other half coming from the funds secured in a Series B round from an investor consortium including Vesalius Biocapital II S.A. SICAR, a SMS Group company, VC Fonds Technologie Berlin, Hightech Gründerfonds II GmbH & Co. KG (HTGF), KfW Group and The Falck Revocable Trust, Ascenion GmbH and members of the management team earlier this year. The project will facilitate further research activities into OMEICOS’ novel approach to treat cardiovascular diseases and to explore its potential in other areas of high unmet medical need. With this renewed support from the German government as part of the Ascenion Spinnovator program, OMEICOS has secured so far roughly €4 million non-dilutive funding.

OMEICOS Announces First Closing of €8.3 Million Series B Financing Round and the Initiation of Phase 1 Clinical Trial

Financing Provides Runway Beyond Completion of First-in-man Trial with Lead Compound OMT-28 for Treatment of Atrial Fibrillation

Berlin, Germany, March 1, 2017

OMEICOS Therapeutics, a biopharmaceutical company developing first-in-class small molecule therapeutics for the prevention and treatment of cardiovascular diseases, today announced the first closing of a Series B financing round of €8.3 million and the initiation of a Phase 1 clinical trial with lead compound OMT-28 for the treatment of atrial fibrillation. The financing was led by Vesalius Biocapital II S.A. SICAR and SMS Company Group, along with existing investors KFW Group, VC Fonds Technologie Berlin, High-Tech Gründerfonds II GmbH & Co. KG (HTGF), The Falck Revocable Trust, Ascenion GmbH and members of the management team. The funding will be used to support the newly initiated clinical program and to further leverage the therapeutic potential of the technology.

OMEICOS Receives BMBF Research Grant to Advance its Novel Approach to Treat Atrial Fibrillation

Berlin, Germany, November 2, 2015

OMEICOS Therapeutics, a biopharmaceutical company developing first-in-class small molecule therapeutics for the prevention and treatment of cardiovascular diseases including atrial fibrillation, today announced the approval of an approximately €1.7 million grant by the German Ministry of Education and Research (BMBF). The grant covers half of the investment needed to advance an OMEICOS’ research project with the other half coming from the funds secured in a Series A round from an investor consortium including Vesalius Biocaptial II S.A. SICAR, a SMS Group company, VC Fonds Technologie Berlin, Hightech Gruenderfonds II GmbH & Co. KG (HTGF) and KfW Group earlier this year. The project will facilitate further research activities into OMEICOS’ novel approach to treat atrial fibrillation using orally available small molecule drug candidates and to explore their potential in other areas of high unmet medical need.

OMEICOS Appoints Dr. Ulrich Dauer as Chief Executive Officer

OMEICOS Therapeutics, a biopharmaceutical company developing first-in-class small molecule therapeutics for the prevention and treatment of cardiovascular diseases including atrial fibrillation (AF), today announced the appointment of Dr. Ulrich Dauer as Chief Executive Officer, effective April 13, 2015.

OMEICOS Therapeutics Raises EUR 6.2 Million in Series A to Advance Lead Candidate in Atrial Fibrillation

Berlin, Germany, April 15, 2015

OMEICOS Therapeutics, a biopharmaceutical company developing first-in-class small molecule therapeutics for the prevention and treatment of cardiovascular diseases including atrial fibrillation (AF), today announced that it has raised EUR 6.2 million in a Series A round. Participating in the round were Vesalius Biocapital II S.A. SICAR, acting as lead; a SMS Group Company; VC Fonds Technologie Berlin; Hightech Gruenderfonds II GmbH & Co. KG (HTGF); and KfW Group. As part of the financing round, the company has received subsidies of EUR 550,000 via Ascenion's Spinnovator, a grant program supported by the German Ministry of Education and Research (BMBF).

"The growing population of AF patients is faced with outdated and extremely limited medical treatment options. Current treatments have insufficient efficacy, risk of severe side effects, and are unable to reduce patient mortality," said Dr. Robert Fischer, Chief Scientific Officer of OMEICOS Therapeutics. "We are grateful for the recognition from our investors that OMEICOS has the potential to develop truly novel drugs to prevent and treat severe cardiovascular diseases such as AF."